- Lantheus (NASDAQ:LNTH) and its affiliates entered agreement with Radiopharm Theranostics – a developer of diagnostic and therapeutic radiopharmaceutical products.
- Lantheus (LNTH) has agreed to make an initial equity investment of A$7.5M ($4.99M) and will have an option to invest a further A$7.5M ($5M) within 6 months on the same terms.
- Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus (LNTH) for A$3M ($2M) pursuant to a separate transfer and development agreement.
- The offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024.
- The net proceeds of Lantheus’ investment will be used by the company for drug manufacturing, clinical trials and general working capital.
